{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:18:18Z","timestamp":1790500698065,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1124\/jpet.119.262733","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T15:55:19Z","timestamp":1578326119000},"page":"24-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone"],"prefix":"10.1016","volume":"373","author":[{"given":"Casandra L.","family":"Larrivee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiah A.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent S.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Leipprandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Y.","family":"Demireva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-0008","authenticated-orcid":false,"given":"Richard R.","family":"Neubig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.262733_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pediatrneurol.2016.02.018","article-title":"Clinical Course of Six Children With GNAO1 Mutations Causing a Severe and Distinctive Movement Disorder","volume":"59","author":"Ananth","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1124\/jpet.119.262733_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1684\/epd.2017.0888","article-title":"GNAO1-associated epileptic encephalopathy and movement disorders: c.607G>A variant represents a probable mutation hotspot with a distinct phenotype","volume":"19","author":"Arya","year":"2017","journal-title":"Epileptic Disord"},{"key":"10.1124\/jpet.119.262733_bib3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/s-0038-1645884","article-title":"Multiple Causes of Pediatric Early Onset Chorea-Clinical and Genetic Approach","volume":"49","author":"Blumkin","year":"2018","journal-title":"Neuropediatrics"},{"key":"10.1124\/jpet.119.262733_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/gim.2017.129","article-title":"Prospective cohort study for identification of underlying genetic causes in neonatal encephalopathy using whole-exome sequencing","volume":"20","author":"Bruun","year":"2018","journal-title":"Genet Med"},{"key":"10.1124\/jpet.119.262733_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0361-9230(03)00020-0","article-title":"Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice","volume":"60","author":"Carvalho","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.1124\/jpet.119.262733_bib6","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/NXG.0000000000000143","article-title":"GNAO1 encephalopathy: broadening the phenotype and evaluating treatment and outcome","volume":"3","author":"Danti","year":"2017","journal-title":"Neurol Genet"},{"key":"10.1124\/jpet.119.262733_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugpo.2016.06.006","article-title":"Alprazolam use and related harm among opioid substitution treatment clients - 12 months follow up after regulatory rescheduling","volume":"36","author":"Deacon","year":"2016","journal-title":"Int J Drug Policy"},{"key":"10.1124\/jpet.119.262733_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/mdc3.12344","article-title":"GNAO1-associated movement disorder","volume":"3","author":"Dhamija","year":"2016","journal-title":"Mov Disord Clin Pract (Hoboken)"},{"key":"10.1124\/jpet.119.262733_bib9","first-page":"Unit9.37","article-title":"Pentylenetetrazol (PTZ) kindling model of epilepsy","volume":"Chapter 9","author":"Dhir","year":"2012","journal-title":"Curr Protoc Neurosci"},{"key":"10.1124\/jpet.119.262733_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajhg.2016.06.003","article-title":"De novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies","volume":"99","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1124\/jpet.119.262733_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ajhg.2014.08.013","article-title":"De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies","volume":"95","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.1124\/jpet.119.262733_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nbd.2018.05.005","article-title":"A mechanistic review on GNAO1-associated movement disorder","volume":"116","author":"Feng","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.119.262733_bib13","doi-asserted-by":"crossref","first-page":"e0211066","DOI":"10.1371\/journal.pone.0211066","article-title":"Mouse models of GNAO1-associated movement disorder: allele- and sex-specific differences in phenotypes","volume":"14","author":"Feng","year":"2019","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.262733_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.0000000000004262","article-title":"Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations","volume":"89","author":"Feng","year":"2017","journal-title":"Neurology"},{"key":"10.1124\/jpet.119.262733_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pediatrneurol.2016.03.011","article-title":"PEHO syndrome may represent phenotypic expansion at the severe end of the early-onset encephalopathies","volume":"60","author":"Gawlinski","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1124\/jpet.119.262733_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.spen.2017.08.008","article-title":"Neonatal epileptic encephalopathy caused by de novo GNAO1 mutation misdiagnosed as atypical Rett syndrome: cautions in interpretation of genomic test results","volume":"26","author":"Gerald","year":"2018","journal-title":"Semin Pediatr Neurol"},{"key":"10.1124\/jpet.119.262733_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/0883073818756134","article-title":"GNAO1 mutation-induced pediatric dystonic storm rescue with pallidal deep brain stimulation","volume":"33","author":"Honey","year":"2018","journal-title":"J Child Neurol"},{"key":"10.1124\/jpet.119.262733_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/371164a0","article-title":"Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function","volume":"371","author":"Iiri","year":"1994","journal-title":"Nature"},{"key":"10.1124\/jpet.119.262733_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00335-014-9509-z","article-title":"Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)?","volume":"25","author":"Kehrl","year":"2014","journal-title":"Mamm Genome"},{"key":"10.1124\/jpet.119.262733_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/epi.14653","article-title":"Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region","volume":"60","author":"Kelly","year":"2019","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.119.262733_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2018.05.018","article-title":"Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia","volume":"391","author":"Koy","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1124\/jpet.119.262733_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0883073815587945","article-title":"Progressive movement disorder in brothers carrying a GNAO1 mutation responsive to deep brain stimulation","volume":"31","author":"Kulkarni","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1124\/jpet.119.262733_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cca.2015.10.011","article-title":"Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy","volume":"451","author":"Law","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1124\/jpet.119.262733_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0076-6879(94)37059-1","article-title":"Expression of G-protein alpha subunits in Escherichia coli","volume":"237","author":"Lee","year":"1994","journal-title":"Methods Enzymol"},{"key":"10.1124\/jpet.119.262733_bib25","doi-asserted-by":"crossref","first-page":"21818","DOI":"10.1074\/jbc.M114.549790","article-title":"Different biochemical properties explain why two equivalent G\u03b1 subunit mutants cause unrelated diseases","volume":"289","author":"Leyme","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.262733_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-016-0416-0","article-title":"GNAO1 encephalopathy: further delineation of a severe neurodevelopmental syndrome affecting females","volume":"11","author":"Marc\u00e9-Grau","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/jpet.119.262733_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.33588\/rn.6609.2018007","article-title":"GNAO1: a new gene to consider on early-onset childhood dystonia","volume":"66","author":"Marecos","year":"2018","journal-title":"Rev Neurol"},{"key":"10.1124\/jpet.119.262733_bib28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0076-6879(02)44730-1","article-title":"Fluorescence approaches to study G protein mechanisms","volume":"344","author":"McEwen","year":"2002","journal-title":"Methods Enzymol"},{"key":"10.1124\/jpet.119.262733_bib29","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1177\/0883073816666474","article-title":"Recurrent GNAO1 mutations associated with developmental delay and a movement disorder","volume":"31","author":"Menke","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1124\/jpet.119.262733_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajhg.2013.07.014","article-title":"De Novo mutations in GNAO1, encoding a G\u03b1o subunit of heterotrimeric G proteins, cause epileptic encephalopathy","volume":"93","author":"Nakamura","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1124\/jpet.119.262733_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/RRS-200029981","article-title":"Dopamine receptor signaling","volume":"24","author":"Neve","year":"2004","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1124\/jpet.119.262733_bib32","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.braindev.2018.06.005","article-title":"A patient with a GNAO1 mutation with decreased spontaneous movements, hypotonia, and dystonic features","volume":"40","author":"Okumura","year":"2018","journal-title":"Brain Dev"},{"key":"10.1124\/jpet.119.262733_bib33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12920-018-0320-7","article-title":"Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing","volume":"11","author":"Rim","year":"2018","journal-title":"BMC Med Genomics"},{"key":"10.1124\/jpet.119.262733_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ejhg.2015.92","article-title":"Phenotypic spectrum of GNAO1 variants: epileptic encephalopathy to involuntary movements with severe developmental delay","volume":"24","author":"Saitsu","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1124\/jpet.119.262733_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2016.11.009","article-title":"A case of severe movement disorder with GNAO1 mutation responsive to topiramate","volume":"39","author":"Sakamoto","year":"2017","journal-title":"Brain Dev"},{"key":"10.1124\/jpet.119.262733_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.parkreldis.2018.11.019","article-title":"Phenomenology and clinical course of movement disorder in GNAO1 variants: results from an analytical review","volume":"61","author":"Schirinzi","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.119.262733_bib37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-0037-1603977","article-title":"Expanding phenotype of de novo mutations in GNAO1: four new cases and review of literature","volume":"48","author":"Schorling","year":"2017","journal-title":"Neuropediatrics"},{"key":"10.1124\/jpet.119.262733_bib38","first-page":"e52434","article-title":"Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice","author":"Seibenhener","year":"2015","journal-title":"J Vis Exp"},{"key":"10.1124\/jpet.119.262733_bib39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/acn3.551","article-title":"Genomic analysis identifies masqueraders of full-term cerebral palsy","volume":"5","author":"Takezawa","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1124\/jpet.119.262733_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X15583717","article-title":"Clinical phenotype of de novo GNAO1 mutation: case report and review of literature","volume":"2","author":"Talvik","year":"2015","journal-title":"Child Neurology Open"},{"key":"10.1124\/jpet.119.262733_bib41","first-page":"51785","article-title":"Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases","author":"Tatem","year":"2014","journal-title":"J Vis Exp"},{"key":"10.1124\/jpet.119.262733_bib42","doi-asserted-by":"crossref","first-page":"14523","DOI":"10.1038\/ncomms14523","article-title":"Dynamic regulation of GDP binding to G proteins revealed by magnetic field-dependent NMR relaxation analyses","volume":"8","author":"Toyama","year":"2017","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.119.262733_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/jnnp-2017-315653","article-title":"GNAO1-related movement disorder with life-threatening exacerbations: movement phenomenology and response to DBS","volume":"89","author":"Waak","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.119.262733_bib44","first-page":"154","article-title":"Recurrent convulsion and pulmonary infection complicated by psychomotor retardation in an infant","volume":"20","author":"Xiong","year":"2018","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"10.1124\/jpet.119.262733_bib45","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00381-016-3139-6","article-title":"Excellent response to deep brain stimulation in a young girl with GNAO1-related progressive choreoathetosis","volume":"32","author":"Yilmaz","year":"2016","journal-title":"Childs Nerv Syst"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.262733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:55:15Z","timestamp":1739955315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0022356524258468"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.262733","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/662031","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.262733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}